Charles River Laboratories trades at $225.41 and has moved in lockstep with the market. Its shares have returned 11.4% over the last six months while the S&P 500 has gained 9.3%.

Is there a buying opportunity in Charles River Laboratories, or does it present a risk to your portfolio? Get the full stock story straight from our expert analysts, it’s free.

Why Is Charles River Laboratories Not Exciting?

We’re swiping left on Charles River Laboratories for now. Here are three reasons why CRL doesn’t excite us, plus one stock we’d rather own.

1. Core Business Falling Behind as Demand Declines

We can better understand Drug Development Inputs & Services companies by analyzing their organic revenue. This metric gives visibility into Charles River Laboratories’s core business because it excludes one-time events such as mergers, acquisitions, and divestitures along with foreign currency fluctuations - non-fundamental factors that can manipulate the income statement.

Over the last two years, Charles River Laboratories’s organic revenue averaged 2% year-on-year declines. This performance was underwhelming and implies it may need to improve its products, pricing, or go-to-market strategy. It also suggests Charles River Laboratories might have to lean into acquisitions to grow, which isn’t ideal because M&A can be expensive and risky (integrations often disrupt focus).

2. Revenue Projections Show Stormy Skies Ahead

Forecasted revenues by Wall Street analysts signal a company’s potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite.

Over the next 12 months, sell-side analysts expect Charles River Laboratories’s revenue to drop by 4.9%, a decrease from its 5.8% annualized growth for the past five years. This projection is underwhelming and suggests its products and services will face some demand challenges.

3. New Investments Fail to Bear Fruit as ROIC Declines

We like to invest in businesses with high returns, but the trend in a company’s ROIC can also be an early indicator of future business quality.

Over the last few years, Charles River Laboratories’s ROIC has unfortunately decreased significantly. Paired with its already low returns, these declines suggest its profitable growth opportunities are few and far between.

Final Judgment

Charles River Laboratories’s business quality ultimately falls short of our standards. That said, the stock currently trades at 19.4× forward P/E (or $225.41 per share). Beauty is in the eye of the beholder, but our analysis shows the upside isn’t great compared to the potential downside. We’re pretty confident there are more exciting stocks to buy at the moment. Let us point you toward the most dominant software business in the world.

Stocks We Like More Than Charles River Laboratories

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.